TRADING UPDATES: Sureserve gets new CFO; Sareum notes GSK buys Sierra

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on ...

Alliance News 13 April, 2022 | 8:59PM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Amati AIM VCT PLC - Edinburgh-based investment company - Says net asset value grew to GBP247.1 million at January 31, from GBP238.3 million a year before. NAV per share drops to 180.7 pence from 206.1p, as the number of shares in issue increases to 136.7 million from 115.6 million. Share price discount to NAV increases to 7.9% from 7.6%. NAV total return falls to loss of 7.5% from a return of 39% the year before. "Some of this fall was for company-specific reasons, in particular Polarean Imaging and Frontier Developments, while some was due to a sharp deterioration in sentiment," Chair Peter Lawrence explains. A final dividend of 4.5p is proposed, bringing full-year total to 9.0p, down year-on-year from 10.5p.

----------

Cellular Goods PLC - London-based consumer products with lab-made cannabinoids - Notes Food Standards Agency's position on new products not on sale before February 2020 not being eligible for public list, and confirms its branded products are manufactured and supplied by Chanelle McCoy Health whose products are validated and on the FSA's permitted list. Will seek clarification with Food Standards Agency's stance on its ingestibles products, noting they are identical to products already approved.

----------

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Notes agreement for Sierra Oncology Inc to be acquired by GlaxoSmithKline PLC. Sierra is the license holder for SRA737, a treatment discovered and developed by Sareum before the license was sold to Sierra. Sierra has several potential clinical trials in the pipeline for SRA737 as a combination treatment for haematologic and solid tumour indications. According to an amended USD299 million licensing deal for the drug, Sareum still has a 28% share of future milestone payments as well as royalties on future sales. "The dosing of the first patient with SRA737 in any new clinical trial would result in a USD2.0m payment from Sierra, with 28% of this due to Sareum," the company explains.

----------

CIP Merchant Capital Ltd - Guernsey-based investment company - Says following the offer from Corporation Financiere Europeenne SA becoming unconditional, it terminates all irrevocable undertakings for its shareholders to not accept any offer from CFE. CFE owns or holds acceptances for 57% of the company. Also notes announcement by Coro Energy PLC on Monday confirming completion of the restructuring of its Luxembourg listed Eurobonds. CIP Merchant holds EUR4.1 million of the EUR11.3 million tranche A eurobonds.

----------

Sureserve Group PLC - Basildon, Essex-based compliance and energy services, focused on UK public sector - Appoints Sameet Vohra as permanent chief financial officer with immediate effect. Vohra has been CFO at Science Group PLC, and director of finance at Spectris PLC.

----------

Gensource Potash Corp - fertilizer development company located in Saskatchewan, Canada - Reaches binding agreement to acquire Innovare Technologies Ltd, "a privately-held developer of patented selective solution mining and brine processing technology for the recovery of potash and other soluble minerals". The deal values Innovare USD11.5 million, and is anticipated to close in the second quarter of this year.

----------

Digital 9 Infrastructure PLC - London-based digital infrastructure investor - Signs binding sale and purchase agreement to acquire GAData Holdings Ltd, which trades as Volta Data Centres, for GBP45 million. "Data centres form a key part of the digital infrastructure backbone. The acquisition of Volta, which was a pipeline investment identified at IPO, adds to our portfolio of data centres which are in key connectivity locations, as D9 continues to build an integrated platform, driving connectivity throughout its investments," Chair Jack Waters explains.

----------

Tertiary Minerals PLC - Cheshire, England-based precious metals mining company - Updates on Pyramid silver-gold project in Nevada, as drilling completed thus far does not return favourable results, and the continuity of mineralisation at depth is not established. Previous soil and rock chip sampling and trenching showed " wide intervals of significant silver and associated gold mineralisation at surface at North Ruth along a zone over 500 metres in length", with additional trenches in February providing further evidence of the surface extent of mineralised zone. "We executed a limited and cost-effective drill program, utilising reverse circulation, to determine if the mineralisation is present at depth but the results have been disappointing. A detailed analysis of the results will be needed before any further exploration is undertaken. Indications are that localised supergene enrichment of silver has resulted in the grades observed at surface," says Managing Director Patrick Cullen.

----------

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Digital 9 Infrastructure Ord 21.20 GBX -0.47 -
Cellular Goods PLC 0.23 GBX 0.00 -
Coro Energy PLC 0.14 GBX 0.00 -
Science Group PLC 415.00 GBX 0.00 -
CIP Merchant Capital Ord
Amati AIM VCT Ord 85.50 GBX 0.00 -
Tertiary Minerals PLC 0.10 GBX 0.00 -
Spectris PLC 3,274.00 GBX 0.61 -
GlaxoSmithKline PLC 1,653.00 GBX 0.76
Sureserve Group PLC
Gensource Potash Corp 5.50 GBX 29.41 -
Sareum Holdings PLC 26.25 GBX 0.00 -
Gensource Potash Corp 0.12 CAD 0.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures